21 results match your criteria: "CardioVid Clinic[Affiliation]"

Article Synopsis
  • Cardiac amyloidosis (CA) is an often overlooked cause of heart failure (HF), highlighting the importance of early detection and timely therapy for better patient outcomes.
  • A global survey with 1,460 physicians revealed that while many have experience diagnosing CA in patients with preserved ejection fraction (HFpEF), systematic screening is not widely practiced, with only 10% conducting routine checks.
  • There is significant variability in screening and management strategies for CA, indicating a need for better education and access to disease-modifying therapies within the HF community.
View Article and Find Full Text PDF
Article Synopsis
  • This study evaluates global differences in the diagnosis and treatment of heart failure with preserved ejection fraction (HFpEF) through an international survey of 1459 physicians, including both cardiologists and non-cardiologists.
  • The survey revealed significant regional variations in HFpEF management, such as differences in natriuretic peptide usage and echocardiographic practices, with cardiologists managing the majority of HFpEF patients.
  • The preferred treatment methods varied by region, with sodium glucose co-transporter-2 inhibitors (SGLT2i) being the most favored first-line treatment, though availability of these drugs differs significantly across locations.
View Article and Find Full Text PDF

Background: Bacteremia represents high rates of morbidity and mortality, especially in developing countries, highlighting the need for a diagnostic method that allows prompt and appropriate patient treatment. This study compared microbiological performance and adherence of two blood culture protocols for the diagnosis of bacteremia.

Methods: Quasi-experimental study conducted between June 2022 and February 2023.

View Article and Find Full Text PDF

Diagnostic and therapeutic practice for Heart Failure with preserved ejection fraction around the world: An international survey.

Curr Probl Cardiol

December 2024

Heart Failure Department and Clinical Investigation Center Inserm1407, Louis Pradel Cardiovascular Hospital, Hospices Civils de Lyon, Claude Bernard University, Lyon, France.

Article Synopsis
  • A survey was conducted among physicians globally to evaluate the real-world practices for diagnosing and treating heart failure with preserved ejection fraction (HFpEF), highlighting a knowledge gap in clinical implementation.
  • 1,460 physicians from 95 countries participated, primarily cardiologists, with most using a 50% ejection fraction cut-off for HFpEF diagnosis; however, only 47.2% utilized formal diagnostic scores.
  • The results showed that while natriuretic peptides were commonly used (87.4%), SGLT2 inhibitors led as the preferred first treatment (54.4%), indicating a need for better education on HFpEF management.
View Article and Find Full Text PDF

Differences in heart failure with preserved ejection fraction management between care providers: an international survey.

Eur J Heart Fail

August 2024

Hôpital Cardiovasculaire Louis Pradel Hospices Civils de Lyon, Heart Failure Department Clinical Investigation Center Inserm 1407 CarMeN Inserm 1060, University Claude Bernard Lyon, Bron, France.

Article Synopsis
  • * A global survey conducted in 2023 revealed that non-cardiologists and cardiologists were less likely than heart failure specialists to utilize certain diagnostic tools and parameters like natriuretic peptides and specific echocardiographic techniques for diagnosing HFpEF.
  • * While SGLT2 inhibitors and diuretics were commonly preferred medications across specialties, there was a notable variation in the selected first-choice drug for HFpEF, with heart failure specialists favoring SGLT2 inhibitors more than cardiologists
View Article and Find Full Text PDF

Introduction: Increased antimicrobial use during the COVID-19 pandemic has raised concerns about the spread of resistant bacteria. This study analyzed the frequency of device-associated infections (DAI) caused by resistant bacteria, the predictors of these infections, and 30-day all-cause mortality in patients with and without COVID-19.

Methods: A retrospective cohort study was conducted on DAI patients admitted to the ICU (intensive care unit) in 20 hospitals in Medellin, Colombia (2020-2021).

View Article and Find Full Text PDF

Introduction: The evidence supporting pharmacological heart failure treatment relies on randomized clinical trials with stringent inclusion and exclusion criteria.

Objectives: Assess the eligibility of outpatients with chronic heart failure for the trials DAPA-HF, EMPEROR-reduced, and PARADIGM-HF, while exploring potential differences among study populations.

Methods: By reviewing medical records, we determined the eligibility rate for each study and evaluated the incidence of heart failure hospitalizations and all-cause mortality during this period.

View Article and Find Full Text PDF

Background: The Fontan procedure is considered one of the most remarkable achievements in paediatric cardiology and cardiac surgery. Its final anatomical objective is a venous return through the superior and inferior vena cava. The complications inherent to this procedure and subsequent failure are its limitations.

View Article and Find Full Text PDF

Purpose Of Review: Describe disparities in diagnosis and management between men and women with advanced heart failure (HF). Our goal is to identify barriers and suggest solutions.

Recent Findings: Women with advanced HF are less likely to undergo diagnostic testing and procedures (i.

View Article and Find Full Text PDF
Article Synopsis
  • The study investigated how age and sex affect treatment and outcomes for heart failure patients, focusing on a group of over 5,000 individuals from the VICTORIA trial.
  • It found that older patients (≥75 years) had more severe symptoms and worse kidney function but used less intensive therapy compared to younger patients.
  • Interestingly, despite receiving less treatment, elderly women had better outcomes than men, and the effects of vericiguat were consistent across different ages and sexes.
View Article and Find Full Text PDF

Endomyocardiofibrosis (EMF) is a restrictive cardiomyopathy characterized by subendocardial fibrosis due to eosinophilic myocardial infiltration. EMF may commonly present with heart failure (HF) or atrial fibrillation (AF). Immunosuppression can be effective in early stages, but not in the chronic phase.

View Article and Find Full Text PDF

Anti-GM-CSF Neutralizing Autoantibodies in Colombian Patients with Disseminated Cryptococcosis.

J Clin Immunol

July 2023

Laboratory of Human Genetics of Infectious Diseases, Necker Branch, Institut National de la Santé et de la Recherche Médicale (INSERM) U1163, Necker Hospital for Sick Children, 24 Boulevard du Montparnasse, Paris, France.

Background: Cryptococcosis is a potentially life-threatening fungal disease caused by encapsulated yeasts of the genus Cryptococcus, mostly C. neoformans or C. gattii.

View Article and Find Full Text PDF

Getting ahead of the game: in-hospital initiation of HFrEF therapies.

Eur Heart J Suppl

December 2022

Institute of Heart Diseases, Cardiology Department, Medical University, Borowska 213, 50-556 Wroclaw, Poland.

Hospitalizations for heart failure (HF) have become a global problem worldwide. Each episode of HF decompensation may lead to deleterious short- and long- term consequences, but on the other hand is an unique opportunity to adjust the heart failure pharmacotherapy. Thus, in-hospital and an early post-discharge period comprise an optimal timing for initiation and optimization of the comprehensive management of HF.

View Article and Find Full Text PDF
Article Synopsis
  • Recent guidelines suggest starting four key heart failure (HF) medications for patients with reduced ejection fraction (HFrEF) at once, but there's uncertainty about how cardiologists view this approach compared to HF specialists.
  • A survey with 615 cardiologists globally revealed that most prefer a traditional sequential treatment method, starting with ACE inhibitors or other recommended therapies.
  • Although many agree that beginning all four medications during initial hospitalization is doable, there's still a preference for the classic approach, indicating a need for research to alter treatment practices.
View Article and Find Full Text PDF

Red blood cell distribution width to predict mortality in heart transplant recipients: a systematic review.

Monaldi Arch Chest Dis

September 2022

Department of Cardiology Research, Torres de Salud National Research Center, Lima; Ingeniería Biomedica, Facultad de Ciencias y Filosofia, Universidad Peruana Cayetano Heredia, Lima; Departamento de Cardiologia, Hospital Nacional Edgardo Rebagliati Martins, Lima.

Red blood cell distribution width (RDW) has been shown to have prognostic value in a number of different clinical settings, such as cardiovascular disease, including heart failure. However, its prognostic value in heart transplant (HT) recipients remains unknown. The aim of this systematic review is to determine the prognostic value of pre-transplant RDW for mortality in HT recipients.

View Article and Find Full Text PDF

The purpose of this study was to quantify the relationship between a drop in end-tidal carbon dioxide (etCO) and occlusion of pulmonary veins (PVs) to find a delta etCO (ΔetCO) able to predict occlusion during PV isolation (PVI) by cryoballoon. We designed a prospective registry. Paroxysmal atrial fibrillation patients who underwent cryoballoon PVI were included.

View Article and Find Full Text PDF
Article Synopsis
  • * Among the 5048 patients analyzed, those with CAD were generally older, predominantly male, and had higher rates of existing conditions like diabetes, as well as a greater need for advanced heart treatment options.
  • * Results showed that patients with CAD had higher rates of cardiovascular death and heart failure hospitalization compared to those without CAD, but vericiguat treatment was found to be effective and safe for both groups.
View Article and Find Full Text PDF

Case Report: Rhinosporidiosis Literature Review.

Am J Trop Med Hyg

December 2020

3Pediatric Infectious Diseases, University of Antioquia, Cardiovid Clinic, Medellín, Colombia.

Rhinosporidiosis is caused by Rhinosporidium seeberi, a pathogen currently considered a fungus-like parasite of the eukaryotic group Mesomycetozoea. It is usually a benign condition, with slow growth of polypoid lesions, with involvement of the nose, nasopharynx, or eyes. The clinical characteristics of a painless, friable, polypoid mass, usually unilateral, can guide the diagnosis, but the gold standard for diagnosis is histopathological findings.

View Article and Find Full Text PDF